Browsing by author "Garmendia, I."

Repository

How to publish

Resources

FAQs

Now showing items 1-5 of 5

FP03.04. Dasatinib improves the antitumor activity of anti-pd-1 in nsclc models by inhibiting treg conversion and proliferation

Redin, E.; Garmendia, I.; Lozano, T.; Serrano, D.; Senent, Y.; Redrado, M.; Villalba, M.; De Andrea, C. E.; Exposito, F.; Ajona, D.; Ortiz Espinosa, S.; Remirez, A.; Bertolo, C.; Sainz, C.; García Pedrero, Juana María (2021)
PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas

Sánchez Canteli, Mario; Granda Díaz, Rocío; Río Ibisate, Nagore del; Allonca Campa, Eva; López Álvarez, Fernando; Agorreta, J.; Garmendia, I.; Montuenga, Luis M.; García Pedrero, Juana María; Rodrigo Tapia, Juan Pablo (2020)
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

Redin, E.; Garmendia, I.; Lozano, T.; Serrano, D.; Senent, Y.; Redrado, M.; Villalba, M.; De Andrea, C. E.; Exposito, F.; Ajona, D.; Ortiz Espinosa, S.; Remirez, A.; Bertolo, C.; Sainz, C.; García Pedrero, Juana María (2021)
The differential impact of SRC expression on the prognosis of patients with head and neck squamous cell carcinoma

Hermida Prado, Francisco José; Granda Díaz, Rocío; Río Ibisate, Nagore del; Villaronga Torres, María de los Ángeles; Allonca Campa, Eva; Garmendia, I.; Montuenga, L. M.; Rodríguez González, René; Vallina Álvarez, Aitana; Álvarez Marcos, César Antonio; Rodrigo Tapia, Juan Pablo; García Pedrero, Juana María (2019)
YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

Garmendia, I.; Pajares, M. J.; Hermida Prado, Francisco José; Ajona, D.; Rodrigo Tapia, Juan Pablo; García Pedrero, Juana María (2019)

Browsing by author "Garmendia, I."

FP03.04. Dasatinib improves the antitumor activity of anti-pd-1 in nsclc models by inhibiting treg conversion and proliferation ﻿

PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas ﻿

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation ﻿

The differential impact of SRC expression on the prognosis of patients with head and neck squamous cell carcinoma ﻿

YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib ﻿

FP03.04. Dasatinib improves the antitumor activity of anti-pd-1 in nsclc models by inhibiting treg conversion and proliferation

PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

The differential impact of SRC expression on the prognosis of patients with head and neck squamous cell carcinoma

YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib